ENSAYOS clínicos

ESTUDIO DE FASE I MULTICÉNTRICO, ABIERTO, DE ESCALADA DE DOSIS Y EXPANSIÓN, PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y ACTIVIDAD ANTITUMORAL PRELIMINAR DE RO7121661, UN ANTICUERPO BIESPECÍFICO CONTRA PD-1/TIM-3, EN PACIENTES CON TUMORES SÓLIDOS AVANZADO
Dr. Ignacio Javier Melero Bermejo - Medical Oncology- ESTUDIO DE RO7121661, EN PACIENTES CON TUMORES SÓLIDOS AVANZADOS Y/O METASTÁSICOS
- Code EudraCT: 2018-000982-35
- Protocol number: NP40435
- Promoter: Roche Farma, S.A.
- LINK TO CLINICAL TRIALS
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
tal vezLE INTERESE
WHAT TECHNOLOGY
DO WE USE?
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

OUR
PROFESSIONALS
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

WHY CHOOSE
THE CLINICA?
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.
